BiX Featured by the Korea Health Industry Development Institute

Hankyung Magazine profiled BiX as a faculty-founded medical AI company established in October 2024 under the vision of expanding and converging biological intelligence with technology. The company aims to move academic advances into clinical practice and improve survival by helping clinicians identify abdominal cancer earlier.

The profile describes three core technologies. BiX combines CT images with medical history, genomic information, blood-test indicators, and other clinical data; tracks tissue changes across time and across related abdominal organs; and restores ultra-low-dose CT images with deep-learning reconstruction so that lower radiation exposure does not prevent reliable interpretation.

DeepScout's pancreatic-cancer proof of concept reached 95% diagnostic accuracy. Rather than stopping at visible tumor detection, the platform is designed to examine pre-cancerous changes and interactions among surrounding organs. BiX plans to connect the software to existing PACS environments as a plug-in so hospitals can adopt it without replacing their established workflow.

The article also outlines the company's financing and commercialization path: KRW 100 million in seed funding in March 2025, KRW 300 million in Pre-A funding from Shinhan Venture Investment in November 2025, and selection for the 2026 TIPS program. BiX is preparing for Korean medical-device authorization while laying groundwork for an FDA pre-submission and overseas expansion.

BiX plans to expand from pancreatic cancer to a full-cycle multimodal platform for liver, biliary-tract, and other abdominal cancers. Its research base includes a medical AI and computer-vision laboratory of about 20 members, while the company team focuses on AI modeling, software architecture, commercialization, and regulatory strategy.